Close Menu

NEW YORK (GenomeWeb) – Guardant Health said today that it has priced its previously announced underwritten public offering of 4.5 million shares of common stock at $71.00 per share.

The company has also granted underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock at the public offering price. Guardant expects resulting gross proceeds of $319.5 million, excluding any exercise of the underwriters' additional share purchase option.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.